Table 1.

Extent of apoptotic cells after exposure of Jurkat and U937 cells to the indicated drugs



Cell type
Name of drug
Jurkat
U937
Control   8 ± 1.2   7 ± 0.98  
AD   20 ± 2.4   18 ± 2.0  
Bortezomib   22 ± 1.98   19 ± 1.9  
ALLN   19 ± 2.5   20 ± 1.7  
AD + bortezomib   72 ± 4.2   74 ± 3.2  
AD + ALLN
 
70 ± 2.8
 
68 ± 3.0
 


Cell type
Name of drug
Jurkat
U937
Control   8 ± 1.2   7 ± 0.98  
AD   20 ± 2.4   18 ± 2.0  
Bortezomib   22 ± 1.98   19 ± 1.9  
ALLN   19 ± 2.5   20 ± 1.7  
AD + bortezomib   72 ± 4.2   74 ± 3.2  
AD + ALLN
 
70 ± 2.8
 
68 ± 3.0
 

Combined treatment with adaphostin (AD) and proteosome inhibitors other than MG-132 (eg, bortezomib and ALLN) interact synergistically to induce cell death in Jurkat and U937 cells. Jurkat and U937 cells were exposed to the indicated drugs alone and in combination for 24 hours, after which the extent of apoptotic cells was determined by flow cytometric analysis after annexin V/PI staining as described in “Materials and methods.” Values represent the means plus or minus SD for 3 separate experiments performed in triplicate. Drug concentrations were as follows: Jurkat: AD, 400 nM; bortezomib, 4.0 nM; ALLN, 4.0 μM; U937: AD, 750 nM; bortezomib, 4.0 nM, ALLN, 4.0 μM.

Close Modal

or Create an Account

Close Modal
Close Modal